Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria

Core Insights - Jasper Therapeutics reported positive preliminary data from the BEACON Phase 1b/2a study of briquilimab, showing rapid and durable clinical responses in patients with chronic spontaneous urticaria (CSU) [2][3][17] - The study demonstrated significant reductions in Urticaria Activity Score over 7 days (UAS7), with a mean change of -26.6 in the 240mg single-dose cohort at 8 weeks [2][6][8] - The company plans to initiate a registrational program for briquilimab in CSU, with a Phase 2b study expected to start in the second half of 2025 [16][17] Study Results - In the BEACON study, 100% of patients in the 240mg single-dose cohort achieved complete responses (UAS7 = 0) at 8 weeks, with 66% maintaining well-controlled disease at 12 weeks [2][6][8] - Multiple dosing regimens at or above 120mg showed UAS7 changes of more than -25 points, indicating substantial clinical activity [2][6][10] - Serum tryptase levels were significantly reduced, with 100% of participants in the 240mg cohort achieving levels below the lower limit of quantification by week 1 [13][14] Safety Profile - Briquilimab was well tolerated, with no dose-limiting toxicities reported and only low-grade adverse events observed [14] - Predictable decreases in neutrophil counts were noted, which generally recovered before subsequent doses [14] Future Plans - Jasper is conducting an open-label extension study for patients transitioning from the BEACON study to a 180mg Q8W dose [15] - The company has submitted for regulatory review of additional BEACON cohorts, including 240mg Q8W and 180mg Q8W following a 240mg induction dose [15][16] - Data from additional cohorts are expected to be presented by mid-2025, further informing the registrational program [16]